The Surveillance, Prevention, and Treatment of Viral Hepatitis: Looking Forward to Global Elimination

Dear Colleagues,

The Special Issue of Livers, entitled "The Surveillance, Prevention, and Treatment of Viral Hepatitis: Looking forward to Global Elimination" is scheduled to provide an in-depth exploration of the critical components necessary for diagnosing and effectively managing viral hepatitis. Moreover, it will be of great importance to include articles dealing with the global efforts and strategies aimed at preventing and eradicating viral hepatitis, which is recognized as a significant public health challenge.

Our aim is to encompass a wide range of topics, including the latest research findings on hepatitis viruses (A, B, C, D, and E), advancements in treatment options, and the implementation of effective public health policies to achieve the goal of viral hepatitis elimination.

The issue will try to highlight the importance of early diagnosis, vaccination, and access to antiviral therapies in the fight against hepatitis. Additionally, it addresses the socio-economic factors influencing hepatitis prevalence and explores innovative approaches to increase awareness and prevention efforts in vulnerable populations.

Overall, this Special Issue aims to serve as a comprehensive resource for healthcare professionals, researchers, and policymakers, providing insights into the multifaceted approach required to improve the surveillance, prevention, and treatment of viral hepatitis.

Dr. Melanie Deutsch
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• viral hepatitis surveillance systems
• preventive measures (preventive strategies, vaccination programs, awareness campaigns, harm reduction initiatives aimed at reducing transmission rates, and targeted prevention efforts for at-risk populations)
• diagnostic innovations: advances in diagnostic technologies and new methods for the early detection of hepatitis viruses
• antiviral therapies for hepatitis B, C, and D (existing treatments and the emergence of new therapeutic options and strategies)
• public health policies in addressing the viral hepatitis epidemic
• challenges and barriers faced in the surveillance, prevention, and treatment of viral hepatitis (healthcare access disparities, stigma, and the need for integrated healthcare approaches)
• collaborative efforts among stakeholders, including governments, healthcare providers, and community organizations, in enhancing hepatitis control
• digital health solutions that aim to improve awareness, education, and access to care for hepatitis patients